logo
  

Great Plains Energy Q3 Profit Declines; Lifts Lower-end Of FY13 EPS Range

Great Plains Energy (GXP) Thursday reported third-quarter net income attributable to common shareholders of $142.7 million or $0.93 per share, compared to $145.8 million or $0.95 per share last year.

On average, 12 analysts polled by Thomson Reuters expected the company to earn $0.93 per share for the quarter. Analysts' estimates typically exclude special items.

Operating revenues for the quarter rose to $765.0 million from $746.2 million a year ago. Analysts expected revenues of $770.25 million for the quarter.

The company also announced it is narrowing its full-year 2013 earnings guidance range from $1.44 to $1.64 per share to $1.54 to $1.64 per share.
Analysts currently estimate earnings of $1.58 per share for the year.

On November 5, 2013, Great Plains Energy announced that its Board of Directors approved a quarterly dividend of $0.23 per share on its common stock. The common dividend will be payable December 20, 2013 to shareholders of record as of November 29, 2013. The shares will begin to trade ex-dividend on November 26, 2013.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT